Merck in $32 Billion Talks for Cancer Drug Breakthrough

Pharmaceutical giant Merck is in discussions to acquire Revolution Medicines for up to $32 billion, according to sources. The deal would give Merck control of a promising new treatment for pancreatic cancer. Revolution Medicines is developing a drug known as RMC-6236. This treatment targets a specific, hard-to-treat cancer mutation called KRAS. The potential agreement highlights the high value placed on new cancer therapies. If completed, the acquisition would be one of the largest biotech deals in recent years. It signals Merck's strategy to strengthen its cancer drug portfolio. The company faces future revenue decline as key patents expire. Merck and Revolution Medicines have not publicly commented on the reported talks. Any final deal would require approval from regulators and Revolution's shareholders.